Unlabelled: Stroke is a serious global illness. Human albumin has emerged as a putative therapy for ischaemic stroke based on strong evidence from animal models. Following confirmation of the safety and feasibility of high-dose albumin treatment for acute ischaemic stroke in a pilot study, the Albumin in Acute Stroke trial, a phase 3 randomised, double-blinded, placebo-controlled clinical trial was initiated to evaluate the efficacy of high-dose albumin compared to saline control within 5 h of ischaemic stroke onset.
Methods: The trial will enrol 1800 patients in two cohorts--a thrombolytic and a nonthrombolytic arm. High-dose (2 g/kg) human albumin will be administered in a 2-h straight intravenous infusion to ischaemic stroke patients, within 5 h of symptom onset. The primary outcome will be an NIH stroke scale score of 0-1 or a modified Rankin scale score of 0-1 at 90 days. Safety outcomes will include the incidence of congestive heart failure after study-drug administration.
Results: Enrolment opened at 40 sites in August 2006; new sites continue to be added. Recruitment is ongoing and is projected to be completed by 2010.
Conclusions: The trial will continue through 2010. The study is proceeding as planned.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1747-4949.2007.00143.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the stroke burden in Saudi Arabia: Trends from 1990 to 2019 and forecasting through time series analysis.
Neurosciences (Riyadh)
January 2025
From the Department of Family and Community Medicine (Mahfouz, Ghazy), College of Medicine, King Khalid University, Abha, Kingdom of Saudi Arabia, from Alexandria Directorate of Health Affairs (Abdelmoneim), Egyptian Ministry of Health and Population, Alexandria, Department of Public Health and Community Medicine (Abdu), Faculty of Medicine, Mansoura University, Mansoura, from Public Health and Community Medicine (AboElela, Shiba), Faculty of Medicine for Girls, Al-Azhar University, Cairo, Neuroscience Center (Alhazzani), King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Objectives: To describe age-standardized incidence and disability-adjusted life years (DALYs) of ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) in the Kingdom of Saudi Arabia (KSA) from 1990 to 2019 and forecast these variables using the Global Burden of Diseases (GBD) data over the next years (2020-2030).
Methods: Poisson regression models were employed to identify significant changes in incidence rate ratios (IRRs) and DALY rates for different stroke types. For time series models, the autoregressive integrated moving average (ARIMA) and exponential smoothing state space (ETS) models were used for forecasting.
Safe Implementation of Treatments in Stroke: a study on intravenous thrombolysis in patients over 80 years of age with acute ischaemic stroke.
BMJ Open
January 2025
Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
Objectives: To investigate the safety and efficacy outcomes of intravenous thrombolysis (IVT) in patients aged >80 years with acute ischaemic stroke (AIS) after IVT was approved in this patient population in several European and non-European countries during 2018-2019.
Design: This is an observational registry study using prospectively collected data from the Safe Implementation of Treatment in Stroke (SITS) registry. Comparisons will be performed between patients treated post-approval (July 2018 to December 2021) period with those treated pre-approval (June 2015 to June 2018) period using propensity score matching (PSM).
Integration of a specialist pharmacist-led multidisciplinary team in primary care: preventing strokes in people with atrial fibrillation across North East London.
BMJ Open Qual
January 2025
Department of Pharmacy, Barts Health NHS Trust, London, UK.
Public Health England outlines a national ambition of anticoagulating 90% of eligible patients with atrial fibrillation (AF) by 2029. In 2019/2020, two out of three boroughs reviewed in this study were in the bottom 10% of boroughs compared with others within England. Stroke National Audit data for these three boroughs from 2019 to 2020 identified that in patients with known AF admitted to hospital with strokes, 37% were not anticoagulated.
View Article and Find Full Text PDFSickness absence and disability pension in patients treated with mechanical thrombectomy.
J Stroke Cerebrovasc Dis
January 2025
Department of Clincal Sciences, Danderyd hospital, Karolinska Institutet, Stockholm, Sweden.
Background: Stroke patients with large vessel occlusions risk long-term or permanent sickness absence. We aimed to analyze the proportions and days of sickness absence and disability pension in thrombectomy-treated patients.
Methods: A register-based nationwide longitudinal cohort study of stroke patients treated with mechanical thrombectomy in 2016-2021 in Sweden (identified through the Swedish Board of Health and Welfare procedural code for care interventions, KVÅ:AAL15).
Visual feature processing in a large stroke cohort: evidence against modular organization.
Brain
January 2025
Faculty of Social and Behavioural Sciences, University of Amsterdam, 1001 NK, Amsterdam, The Netherlands.
Mid-level visual processing represents a crucial stage between basic sensory input and higher-level object recognition. The conventional model posits that fundamental visual qualities like color and motion are processed in specialized, retinotopic brain regions (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!